The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study

Sandvik, Elfrid Christine Smith; Aasarød, Kristin Matre; Johnsen, Gjermund; Hoff, Dag Arne Lihaug; Kulseng, Bård; Hyldmo, Åsne Ask; Græslie, Hallvard; Nymo, Siren; Sandvik, Jorunn; Fossmark, Reidar

doi:10.3390/jcm11164910

Cited by 5 publications

(3 citation statements)

References 40 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nascimento et al analyzed changes in NAFLD Fibrosis Score before and after bariatric surgery. The NAFLD Fibrosis Score changed from −0.6845 before the surgery to −1.6898 12 months after the procedure (p < 0.0002), indicating an absence of advanced liver fibrosis in any patient 12 months after the surgery [35] In the above-mentioned study, a weak negative correlation between the decrease in NAFLD Fibrosis Score and weight loss parameters (%EWL (r = −0.251, p < 0.0001) and %TWL (r = −0.280, p < 0.0001)) was observed [37]. In our study, a statistically significant decrease in NAFLD Fibrosis Score was also seen.…”

Section: Discussionmentioning

confidence: 81%

“…Sandvik et al observed a significant overall shift towards lower risk categories of advanced hepatic fibrosis based on NAFLD Fibrosis Score in 11.6 years of observation (NAFLD Fibrosis Score −1.32 (IQR −2.33; −0.39) vs. −1.71 (IQR −2.49; −0.95, p < 0.001) 11.6 years after surgery). In the above-mentioned study, a weak negative correlation between the decrease in NAFLD Fibrosis Score and weight loss parameters (%EWL (r = −0.251, p < 0.0001) and %TWL (r = −0.280, p < 0.0001)) was observed [ 37 ]. In our study, a statistically significant decrease in NAFLD Fibrosis Score was also seen.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Laparoscopic Sleeve Gastrectomy on the Course of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients during One Year of Follow Up

Głuszyńska

Łukaszewicz

Diemieszczyk³

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Morbid obesity co-exists with non-alcoholic fatty liver disease in up to 90% of cases. Laparoscopic sleeve gastrectomy leads to a reduction in body mass and thus may improve the course of non-alcoholic fatty liver disease. The aim of this study was to evaluate the effect of laparoscopic sleeve gastrectomy on the resolution of non-alcoholic fatty liver disease. Methods: The study included 55 patients with non-alcoholic fatty liver disease who underwent laparoscopic sleeve gastrectomy at a tertiary institution. The analysis consisted of preoperative liver biopsy, abdominal ultrasound, weight loss parameters, Non-Alcoholic Fatty Liver Fibrosis Score and selected laboratory parameters. Results: Before the surgery, 6 patients were diagnosed with grade 1 liver steatosis, 33 patients with grade 2 and 16 patients with grade 3. One year after the surgery, only 21 patients had features of liver steatosis at ultrasound. All weight loss parameters showed statistically significant changes during the observation; the median percentage of total weight loss was 31.0% (IQR: 27.5; 34.5) with p = 0.0003, the median percentage of excess weight loss was 61.8% (IQR: 52.4; 72.3) with p = 0.0013 and the median percentage of excess body mass index loss was 71.0% (IQR: 61.3; 86.9) with p = 0.0036 12 months after laparoscopic sleeve gastrectomy. The median Non-Alcoholic Fatty Liver Fibrosis Score at baseline was 0.2 (IQR: −0.8; 1.0) and decreased to −1.6 (IQR: −2.4; −0.4) (p < 0.0001). Moderate negative correlations between Non-Alcoholic Fatty Liver Fibrosis Score and percentage of total weight loss (r = −0.434, p < 0.0001), percentage of excess weight loss (r = −0.456, p < 0.0001) and percentage of excess body mass index loss (r = −0.512, p < 0.0001) were found. Conclusions: The study supports the thesis that laparoscopic sleeve gastrectomy is an effective method for treatment of non-alcoholic fatty liver disease in patients with morbid obesity.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

The Effect of Laparoscopic Sleeve Gastrectomy on the Course of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients during One Year of Follow Up

Głuszyńska

Łukaszewicz

Diemieszczyk³

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Other nonlipoprotein biomarkers of metabolic syndrome are summarized in Table 2[83–90,91 ▪ ,92,93–100,101 ▪ ,102,103–107].…”

Section: Novel Cardiovascular Risk Factors and Metabolic Syndromementioning

confidence: 99%

Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery

Bashir,

Adam,

et al. 2023

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review The aim of this study was to provide an overview of the role of novel biomarkers in metabolic syndrome, their association with cardiovascular risk and the impact of bariatric surgery on these biomarkers. Recent findings Metabolic syndrome encompasses an intricate network of health problems, and its constituents extend beyond the components of its operational definition. Obesity-related dyslipidaemia not only leads to quantitative changes in lipoprotein concentration but also alteration in qualitative composition of various lipoprotein subfractions, including HDL particles, rendering them proatherogenic. This is compounded by the concurrent existence of obstructive sleep apnoea (OSA) and nonalcoholic fatty liver disease (NAFLD), which pave the common pathway to inflammation and oxidative stress culminating in heightened atherosclerotic cardiovascular disease (ASCVD) risk. Bariatric surgery is an exceptional modality to reverse both conventional and less recognised aspects of metabolic syndrome. It reduces the burden of atherosclerosis by ameliorating the impact of obesity and its related complications (OSA, NAFLD) on quantitative and qualitative composition of lipoproteins, ultimately improving endothelial function and cardiovascular morbidity and mortality. Summary Several novel biomarkers, which are not traditionally considered as components of metabolic syndrome play a crucial role in determining ASCVD risk in metabolic syndrome. Due to their independent association with ASCVD, it is imperative that these are addressed. Bariatric surgery is a widely recognized intervention to improve the conventional risk factors associated with metabolic syndrome; however, it also serves as an effective treatment to optimize novel biomarkers.

show abstract

Effect of Transoral Outlet Reduction on Hepatic Fibrosis in Roux-en-Y Gastric Bypass Patients with Weight Regain and Non-alcoholic Fatty Liver Disease

2023

View full text Add to dashboard Cite

The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study

Cited by 5 publications

References 40 publications

The Effect of Laparoscopic Sleeve Gastrectomy on the Course of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients during One Year of Follow Up

The Effect of Laparoscopic Sleeve Gastrectomy on the Course of Non-Alcoholic Fatty Liver Disease in Morbidly Obese Patients during One Year of Follow Up

Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery

Effect of Transoral Outlet Reduction on Hepatic Fibrosis in Roux-en-Y Gastric Bypass Patients with Weight Regain and Non-alcoholic Fatty Liver Disease

Contact Info

Product

Resources

About